Results 101 to 110 of about 5,502 (160)

Fluorinated Aminopiperidones as Non-Glutarimide Thalidomide Analogs: Stereodivergent Synthesis and Validation. [PDF]

ChemMedChem
Adamlje B, Tomašič T, Steinebach C, Ebeling S, Herrmann A, Hartmann MD, Horner JL, Bhadresha K, Chau CH, Figg WD, Sosič I, Cotman AE.   +11 more
europepmc   +1 more source

Fusion Molecules Between the STAT5b Inhibitor Stafib-2-CR and a Cereblon Ligand. [PDF]

ChemistryOpen
Münzel T, Seidenstücker KC, Protzel C, Berg A, Berg T.   +4 more
europepmc   +1 more source

Therapeutic Horizon in Multiple Myeloma: Analysis of the Emerging Landscape of Clinical Trials. [PDF]

Ther Innov Regul Sci
Rodrigues MA, de Pádua CAM, de Miranda Drummond PL, Malta JS, Reis AMM.   +4 more
europepmc   +1 more source

Targeted protein degradation bypassing cereblon and von Hippel-Lindau

The Innovation, 2023
Wenchao Lu
doaj   +1 more source

Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations. [PDF]

J Med Chem
Wang C, Ghosh P, Jin S, Bai L, Aguilar A, McEachern D, Wang M, Li Q, Wen B, Sun D, Wang S.   +10 more
europepmc   +1 more source

Targeting Ikaros and Aiolos: Next-Generation Cereblon E3 Ligase Modulators in MM. [PDF]

Eur J Haematol
Alvaro ME, Martino EA, Caserta S, Skafi M, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Mendicino F, Vigna E, Morabito F, Gentile M.   +12 more
europepmc   +1 more source

The role of cereblon-AMPK (AMP-activated protein kinase) axis in osteoarthritis and development of disease-modifying osteoarthritis drugs

Osteoarthritis (OA), now recognized as a whole-joint disease, involves cartilage destruction, subchondral bone sclerosis, osteophyte formation, and synovial inflammation.
이연
core  

Acyclic Glutarimide PROTAC Precursors Enable Controlled Protein Degradation and Expand Cereblon Ligand Space. [PDF]

ACS Med Chem Lett
Renner AC, Kargbo RB.
europepmc   +1 more source

EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway. [PDF]

Haematologica
Li Y, Wilson A, Chrisochoidou Y, Martin S, Bird S, Morales S, Leiro M, Kozik Z, Crump NT, Roumeliotis TI, Choudhary J, Pawlyn C.   +11 more
europepmc   +1 more source

Advances in multiple myeloma: key updates from the ASH 2025 meeting. [PDF]

J Hematol Oncol
Naing PT, Baljevic M.
europepmc   +1 more source